| 영문 | activation | 한글 | 활성, 활성화 |
|---|---|---|---|
| 설명 | 일반적으로, 생체나 생체 물질이 그 기능을 활발하게 나타내게 되는 것, 예를 들면 ① 촉매 등에서, 그 표면 상태의 변화나, 다른 물질의 첨가 등에 의하여, 그 기능이 현저하게 높아지는 것. ② 효소전구체의 활성화로서 효소작용을 가지지 않는 효소 전구체가 활성있는 효소로 변화는 것. 또 황화수소나 시안화수소산 등으로 파파인이 활성화되는 경우도 있다. |
||
| 영문 | connective tissue | 한글 | 결합조직 |
|---|---|---|---|
| 설명 | 체내에 널리 분포하며, 장기, 조직사이를 메우고 그것을 기계적으로 지지, 조직이다. 그밖에 혈관, 림프관, 신경을 인도하며 영양, 대사산물의 수송 또는 저류, 나아가서는 손상, 감염에 대한 방어 또는 수복 등에도 작용한다. 결합조직은 세포간질이 풍부하며, 세포간질을 구성하는 기질과 섬유의 성상에 따라 간엽조직, 섬유성 결합조직(성긴섬유성 결합조직, 촘촘한 섬유성 결합조직), 지방조직, 탄성조직, 세망 조직 등으로 분류된다. |
||
| 영문 | osseous tissue | 한글 | 뼈조직, 골조직 |
|---|---|---|---|
| 설명 | 골세포와 골세포주위의 딱딱한 칼슘조직으로 둘러싸인 밀집된 결합조직을 뜻한다. 이 골조직에 의해서 뼈가 이루어져 인체의 골격을 형성한다. |
||
| 영문 | epithelial tissue | 한글 | 상피조직 |
|---|---|---|---|
| 설명 | 상피는 한 층 또는 여러 층의 세포로 이루어진 판 모양의 구조로 신체의 표면과 관상구조의 내강을 둘러싸고 있다. 상피세포와 상피세포사이의 적은 양으로 존재하여 상피사이의 공간을 채우고 있는 세포간질을 합쳐 상피조직이라 한다. 상피조직에는 원칙적으로 혈관이 분포되어 있지 않다. |
||
| 영문 | granulation tissue | 한글 | 육아조직 |
|---|---|---|---|
| 설명 | 모세혈관이 풍부하며 왕성하게 증식을 계속하는 어린 결합조직. 창상 등 조직 결손에 대한 수복, 이물처리의 기질화, 염증이 만성적인 경과에 있거나 종양증식에 동반된 사이물질의 반응성 염증에서 관찰된다. 구성성분은 생긴지 얼마 안되는 어린 육아조직은 섬유모세포의 증식, 새로 생긴 모세혈관과 여러 유주세포 및 다른 중간엽세포(백혈구, 림프구, 형질세포, 조직구, 단핵구, 거대세포)등으로 구성된다. 이것이 시간이 지나 그리되면, 모세혈관과 유주세로, 다른조직성분을 감소시켜 만성화하여 오래된 육아가 되며 결국은 섬유세포와 아교질섬유로 구성된 반흔조직으로 변한다. |
||
| TPAI | tissue plasminogen activator inhibitor |
|---|---|
| BPTI | basic pancreatic trypsin inhibitor; basic polyvalent trypsin inhibitor; bovine pancreatic trypsin in... |
| PI | first meiotic prophase; isoelectric point; pacing impulse; package insert; pancreatic insufficiency;... |
| APSAC | 1) Acylating the Plasminogen Streptokinase Activated Complex 2) Anisoylat... |
| APSAC | acylated plasminogen-streptokinase activator complex; anisoylated plasminogen streptokinase activato... |
| PA | Plasminogen activation |
|---|---|
| r-tPA | Recombinant Tissue-Type Plasminogen Activator |
| rt-PA | Recombinant human tissue plasminogen activator |
| rt-PA | Recombinant human tissue-type plasminogen activator |
| r-TPA | Recombinant tissue plasminogen activator |
| plasminogen activator inhibitor 1 | <chemical> A member of the serpin family of proteins. It inhibits both the tissue-type and urokinase-type plasminogen activator. Pharmacological action: serine proteinase inhibitors. (12 Dec 1998) |
|---|---|
| plasminogen activator inhibitor 2 | <chemical> Member of the serpin family of proteins. It inhibits both the tissue-type and urokinase-type plasminogen activator. Pharmacological action: serine proteinase inhibitors. (12 Dec 1998) |
| tissue plasminogen activator | <enzyme> Plasma serine protease, one of a closely related group of plasminogen activators. Contains an EGF like domain and multiple copies of the kringle domain. (18 Nov 1997) |
| tissue-inhibitor of metalloproteinase-1 | <chemical> A member of the family of tissue inhibitor of metalloproteinases. It is a n-glycosylated protein, molecular weight 28 kD, produced by a vast range of cell types and found in a variety of tissues and body fluids. It has been shown to suppress metastasis and inhibit tumour invasion in vitro. Pharmacological action: antineoplastic agent, protease inhibitors. (12 Dec 1998) |
| tissue inhibitor-of metalloproteinase-2 | <chemical> A member of the family of tissue inhibitor of metalloproteinases. It is a 21 kD nonglycosylated protein found in tissue fluid and is secreted as a complex with progelatinase a by human fibroblast and uncomplexed from alveolar macrophages. An overexpression of timp-2 has been shown to inhibit invasive and metastatic activity of tumour cells and decrease tumour growth in vivo. Pharmacological action: antineoplastic agent, protease inhibitors. (12 Dec 1998) |
| tissue inhibitor of-metalloproteinase-3 | <chemical> A member of the family of tissue inhibitor of metalloproteinases. It is a 21 kD, nonglycosylated protein. Timp-3 does not show a high degree of structural similarity unlike timp-1 and timp-2 which are structurally similar. However, it does possess a high degree of structural similarity with that of chicken timp-3 (chimp-3). Human timp-3 is of particular concern because of its potential role in cancer, arthritis, and eye diseases. Pharmacological action: antineoplastic agent, protease inhibitors. (12 Dec 1998) |
| tissue inhibitor of metalloproteinases | <chemical> A family of secreted proteins (timp-1, timp-2, and timp-3) that play a crucial role in regulating the activity of the secreted metalloproteinases (collagenases, stromelysins, gelatinases). Of the three characterised, only timp-1 and timp-2 appear to have related primary structures and inhibitory properties. They influence the activation of the prometalloproteinase and act to modulate proteolysis of extracellular matrix, notably during tissue remodeling and inflammatory processes. On certain cell types, they can exhibit growth factor-like activity, and they can inhibit the tumourigenic and metastatic phenotype in cancer cells. (pharmacol ther 1993;59:329-41) Pharmacological action: antineoplastic agent, protease inhibitors. (12 Dec 1998) |
| plasminogen | <enzyme> The inactive precursor of plasmin. (18 Nov 1997) |
| plasminogen activator | <enzyme> Serine protease that acts on plasminogen to generate plasmin. Has also been implicated in invasiveness and is produced by many normal and invasive cells. The vascular form (tPA, 55 kD) is very similar to tissue plasminogen activator (uPA, 70 kD) and to streptokinase and urokinase. (18 Nov 1997) |
| plasminogen inactivators | <chemical> Important modulators of the activity of plasminogen activator. Four inhibitors, all belonging to the serpin family of proteins, have been implicated in plasminogen activation inhibition. They are pai-1, pai-2, protease-nexin, and protein c inhibitor (pai-3). All inhibit both the tissue-type and urokinase-type plasminogen activator. Pharmacological action: serine proteinase inhibitors. (12 Dec 1998) |
| kidney plasminogen activator | <protein> A precursor to the enzyme urokinase that has blood clotting properties. (14 Nov 1997) |
| activation | <radiobiology> Activation occurs when a particle interacts with an atomic nucleus, shifting the nucleus into an unstable state, and causing it to become radioactive. In fusion research, where deuterium-tritium is a common fuel mixture, the neutron released when (D + T) combine to form (4He + n) can activate the reactor structure. In this case the 4He is inert, the neutron sticks to another nucleus, and the neutron + nucleus reaction creates an actvation product. Sometimes called radioactivation. See: activation product, activation analysis. (09 Oct 1997) |
| activation analysis | <radiobiology> Method for identifying and measuring chemical elements in a sample of material. Sample is first made radioactive by bombardment with neutrons, charged particles, or gamma rays. Newly formed radioactive atoms in the sample then give off characteristic radiations (such as gamma rays) that tell what kinds of atoms are present, and how many. (09 Oct 1997) |
| activation energy | <chemistry> The amount of energy (expressed in joules) that is needed to convert all the molecules in one mole of a reacting substance from a ground state to the transition state. (06 May 1997) |
| activation product | <radiobiology> The unstable nucleus formed when activation occurs. (See activation above.) (09 Oct 1997) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|